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Remote Dianions in the Synthesis of 
Indolizidine Alkaloids 
Indolizidine alkaloids are an important class of compounds possessing diverse and 
potent biological activities. A novel synthetic route for the preparation of these alkaloids 
has been developed. The addition of the "remote" dianion of 4-(phenylsulfonyl)-butanoic 
acid (4-PSBA) to boron trifluoride etherate activated imines has been used to form 2-
r,, .• ,. s. Extension of this methodology to the addition of the "remote" dianion of 
4-PSBA to side-chain functionalized imines has provided 2-piperidones (lactams) that 
have been further manipulated to indolizidines. Further, the dianion addition-cyclization 
reaction sequence has been shown to proceed with diastereoselectivity. In the case of 
a chirally substituted imine, the reaction has been shown to proceed with 
enantioselectivity. This methodology has been employed in the synthesis of 5-coniceine 
and (+)-(IS, 8aS)-l-hydroxyindolizidine. The lactams synthesized are useful 
intermediates for elaboration to a wide variety of indolizidine alkaloid natural products. 
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The Indolizidine Alkaloids 
Chapter I 
Introduction 
Indolizidine alkaloids possess the 1-azabicyclo[4.3.0]nonane skeletal 
structure 1. The generally accepted numbering convention is also 
indicated. The simplest compound of this class is indolizidine itself, also 
known as 8-coniceine (1). In early literature references, this molecule also 
was referred to as octahydroindolizine, octahydropyrindole, piperolidine, 
and octahydropyrrocoline. 
l 
The indolizidine structure is found in a wide variety of natural 
products originating from plant, fungal, and animal sources. The more 
complex indolizidine natural products include (-)-swainsonine (2), ( + )-
castanospermine (J.), (±)-slaframine (i), (-)-monomorine (.5,), and the 
gephyrotoxins ~- These compounds are of great current interest due to 
very interesting and diverse biological properties. 
HO 
-•111111QH 
OAc 
J. 
.6. R1= alkyl 
R2= H, alkyl 
R3= H, alkyl 
2 
3 
Isolation and Biological Activities of Indolizidine Alkaloids 
(-)-Swainsonine, ( 1S ,2R ,SR ,8aR)-l ,2,8-trihydroxyindolizidine (Z), is 
isolable from the fungi Rhizoctonia leguminicola 1 and Metarhizium 
anisopliae F36222 as well as the plants Swainsona canescens , 3 Astragalus 
lentigenosus (locoweed),4 Astragalus emoryanus 5 and Oxytropis sericea.4 
Swainsonine is a potent inhibitor of mammalian lysosomal a-mannosidase, 
which functions in the degradation of the oligosaccharide portion of 
various glycoproteins.6 .2. also has been shown to inhibit Golgi 
mannosidase II. 7 The inhibition of these mannosidases was determined to 
be very specific as swainsonine does not inhibit other glycosidases 
including other mannosidases, and the inhibition appears to be of the 
competitive type. 8 The inhibition of a-mannosidase indicates possible 
interference in the biosynthesis of N-linked glycoproteins. Experimental 
results showed that swainsonine altered the oligosaccharide structure of the 
glycoproteins studied although this change resulted in insignificant effects 
on the cellular secretion and routing of the glycoproteins.9 .2. was found 
not to inhibit the degradation of non-glycoproteins. 10 
In mammals, swainsonine was found to be the causative agent of 
locoism from the ingestion of locoweed. 11 Abortion, birth defects and 
sometimes death can be caused by locoweed consumption. The effects are 
due to both the lysosomal a-mannosidase inhibition and the abnormal 
glycoprotein processing, which results in the storage of abnormally 
processed asparagine-linked gl ycans. 12 Therapeutically, swainsonine has 
been shown to be an immunomodulator that could have possible 
applications in cancer chemotherapy .13 
4 
Castanospermine CJ.), (1S,6S,7R,8R,8aR)-1,6,7,8-
tetrahydroxyindolizidine, has been isolated from Castanospermum 
australe, 14 a leguminous tree indigenous to Australia. These trees are also 
now found in southern California as ornamentals. J. is found in the leaves, 
bark and seeds of the tree, with mature seeds containing the largest 
concentration (0.3% ). 15 Consumption of the seeds results in severe 
gastroenteritis, which is often fatal in cattle. Human poisoning from raw 
seeds has also been reported. 16 
Castanospermine has been found to be a potent and specific inhibitor 
of ~-glucosidase. In general, other glycosidases are not inhibited by J, one 
exception being fibroblast extracts that contain a lysosomal a-glucosidase, 
which is also susceptible to inhibition by this alkaloid. 15 At pH 6.5, 
castanospermine was determined to be a competitive inhibitor of~-
glucosidase.17 It has been determined that the sometimes fatal 
gastrointestinal disorder in animals which have ingested Castanospermum 
australe seeds is due to the presence of castanospermine.18 In high doses, J 
also inhibits intestinal maltase and sucrase causing severe diarrhea. This 
effect has been overcome by inclusion of glucose in the diets of test 
animals. 19 Recent reports indicate that the glycoprotein processing 
inhibition may enable J. to find applications as an antitumor agent,20-24 
antiviral,25-29 and anti-AIDS agent.30,31 
Also present in the seeds of the Castanospermum australe are small 
quantities of 6-epi-castanospermine (11. This compound is a very weak 
inhibitor of ~-glucosidase, but a potent inhibitor of amyloglucosidase. 32 
This specificity emphasizes the importance of the stereochemical 
arrangement in determining the inhibitory potency. 
HO 
1 
The specificity of these glycosidase inhibitors has been 
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theorized to be due to the structural resemblance of the alkaloid to the 
specific sugar of which processing is inhibited (see Figure 1). The 
corresponding glycopyranosyl cations of the sugars are likely intermediates 
in reactions catalyzed by the glycolases, again structurally resembling the 
protonated form of the indolizidines, the predominant species at biological 
pH. Molecular modeling studies have been done to produce an inhibition 
model that fits the known data for these enzyme binding reactions and 
perhaps allows for the prediction of inhibition by new substrates.33 
FIGURE 1 
HO OH 
OH 
Structural similarity between swainsonine and D-mannose 
HO OH 
> 
OH 
Structural similarity between castanospermine and D-glucose 
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Slaframine ~' (1S,6S,8aS)-l-acetoxy-6-aminoindolizidine, is 
isolated from the fungus Rhizoctonia leguminicola. 34 This fungus is also a 
source of swainsonine (2), and both .2. and~ are biosynthesized from the 
same intermediate- pipecolic acid via (IS ,8aS)- l -hydroxyindolizidine (B.). 35 
Slaframine causes excessive salivation in cattle grazing on fungus-infected 
red clover hay. 36 ~ is not bioactive as shown, but is oxidized in vivo into a 
compound that associates with muscarinic acetylcholine receptors.37 This 
interaction indicates the possible use of~ to locate acety lcholine receptor 
7 
sites. Additionally, slaframine has been cited as a possible therapeutic for 
the relief of symptoms associated with cystic fibrosis. 38 
Monomorine I (.S.) has been isolated from Monomorium pharaonis 
L., the Pharaoh ant.39 It is one of the more important trail hormones of 
this species.40 Interest in this alkaloid arises due to the possibility of 
pheromonal control of Pharoah ants, common pests in European hospitals 
that carry harmful bacteria and often escape normal pesticidal control. 
The gephyrotoxin alkaloids ~ consist of 22 natural products which 
have been isolated from the skin secretions of the neotropical poison-dart 
frogs belonging to the genus Dendrobates.41 These alkaloids vary in 
substitution patterns from single substituents at C-5 to substitution at C-3 
and C-5 or C-5 and C-8. Many of the structures of the bicyclic 
gephyrotoxins have not yet been completely elucidated. These alkaloids are 
potent competitive inhibitors of neuromuscular transmission.42 
Pharmacologically, these compounds are of interest in that the 
stereochemical requirements of the acetylcholine receptor complex binding 
site may be probed, providing for possible applications in neurotoxin and 
Alzheimer's research. 
8 
Previous Syntheses 
Synthetic strategies for the preparation of the indolizidine alkaloids in 
both racemic and optically active forms have been the subject of many 
recent reports. Several excellent reviews covering the syntheses of 
compounds of this class are available, with updated reports appearing 
regularly in several sources.43·45 This review is limited to those 
indolizidines that either have been prepared or can be easily accessed from 
the intermediates presented in this dissertation. 8-coniceine (1) was first 
synthesized in 1885 by Hofmann,46with the structure of the product yet 
unknown. The structure was later confirmed in an 1890 synthesis by 
Lellman.47 Although this molecule is not a naturally occurring alkaloid, it 
provides an ideal model target molecule to show the viability of synthetic 
strategies directed toward the preparation of this class of compounds. In 
fact, synthetic interest in this simple bicyclic system has produced no fewer 
than 34 literature reports of the synthesis of 8-coniceine. Hofmann utilized 
the cyclization of N-bromoconiine with sulfuric acid for the first synthesis 
of 1. This method has become known as the Hofmann-Loffler-Freytag 
reaction and has been employed and refined by several groups in the 
synthesis of (±)-8-coniceine as well as optically active ( + )-1 (an=+9.3,c 
1.77, ethanol) and (-)-1 (an=-10.2,c 1.76, ethanol).48·50 In addition, this 
method was extended to include the preparation of 3-methylindolizidine.51 
Schell et al. have obtained (±)-1 via a silver induced rearrangement of N-
9 
chlorogranatine.52 Several groups have utilized a variety of cyclization 
conditions with 2-(3-hydroxypropyl)-piperidine to obtain (±)-o-coniceine 
in varying yields ( 42-85% ).53-58 The distinguishing characteristics of the 
synthesis of 1 by Danishefsky and co-workers include hetero-mercuration 
followed by reductive coupling. 59 The synthesis of 1 by Branchaud effects 
one-step closure of both the five- and six-membered rings while exploring 
the use of the tritylsulfenyl nitrogen protecting group.60 Meyers et al. have 
used the alkylation of a-metallo-formamidines in the development of a 
general route to 1-azabicyclic compounds, including 1. 61 Hua and co-
workers have utilized the annulation of an a-sulfinyl ketimine anion to 1,3-
diiodopropane as a key step to produce 1.62,63 In a somewhat different 
approach, annulation of the six-membered ring onto the five-membered 
ring of chiral pro line derivatives has provided (-)-1 as well as ( + )-
(1 S ,8aS )-1-hydroxyindolizidine. 64 Three groups have reported the 
synthesis of o-coniceine employing transannular ring cyclizations. 65-67 
Stevens et al. utilized a cyclopropylimine rearrangement as a key step in 
the synthesis of 1. 68 Improvements on this synthesis have been reported 
recently by Pearson and coworkers.69,70 The subsequent cyclization of the 
N-alkyl intermediate (at the a-position) represents a ring formation 
common to several subsequent syntheses. For example, Hart and Tsai 
utilized the cyclization of a-acylamino radicals; 71 Shono et al. employed a 
[3+3]-type annelation;72 and Gmeiner and Lerche utilized an intramolecular 
cationic cyclization onto the 2-position of a pyrrole derivative. 73 Pizzomo 
and Albonico employed 1,3-dipolar cyclization as the key step in the 
10 
synthesis of l in a synthetic strategy which could be applied to a variety of 
octahydroindolizidines.74 Weinreb's group utilized the intramolecular 
imino Diels-Alder reaction to produce 1 75 while Gavina and co-workers 
employed the reaction of 2-aza-2,4-cyclopentadienone as a dienophile in the 
Diels-Alder process as a key step in the synthesis.76,77 Radical additions to 
alkenes followed by cyclization steps similar to those of Danishefsky and 
co-workers have provided l as well as l-hydroxyindolizidine.78 
The conformation of 1 has been investigated. Although cis and trans 
fused isomers cannot be isolated due to rapid inversion at nitrogen, the 
presence of Bohlmann bands in the IR and calculations of the free energy 
differences of the conformers ( +2.4 kcal/mol) indicate that the trans 
geometry predominates.79 This conformation has been confirmed by 1 H 
NMR analysis of 1 and it's hydrobromide salt.48 One additional report 
gives 13c NMR data for 1. 80 
Syntheses of .2. and l have mainly been accomplished utilizing 
carbohydrate derived starting materials, with only a few groups using non-
carbohydrate based starting materials. The obvious advantage of 
carbohydrate precursors is the preset configurations of the chiral centers. 
The main drawback to these approaches lies in the difficulty of analogue 
preparation (especially deoxy analogues) as well as lack of versatility in the 
preparation of other non-oxygenated indolizidines such as .5. and n. 
There have been eleven syntheses of swainsonine reported in the 
literature through 1990, of which only the methods of Sharpless et al.81 
and Hart et al. 82 use non-carbohydrate based starting materials. The 
11 
former method produced 2. in 6.6% overall yield from N-benzyl-p-
toluenesulfonamide incorporating the well-known asymmetric epoxidations 
for the introduction of chiral centers. The latter strategy employed D-
tartaric acid as the chiral precursor for the production of .2. via an a-
acylamino radical cyclization. The syntheses of l. by Richardson et al. 83 
and Suami et al.84 provided (-)-swainsonine in 3.3% and 4.0% yields, 
respectively, from similar mannose derived starting materials and 
following analogous routes. The synthetic method developed by Fleet and 
co-workers85 yielded 2. in 21 % yield, again from a mannose derived 
starting material with two consecutive reductive aminations effecting ring 
closure of both rings. The reported syntheses of 2. by Takaya et al86 • and 
Hashimoto et al. 87 utilize D-mannose as the chiral precursor. The former 
process follows a similar route to that of Fleet's group, yet the differences 
result in very poor yields (0.3% ). The latter method employs a one-step 
cyclization of an epoxy amine ester as the key step, but provides 2. in only 
3% overall yield. A method for the preparation of swainsonine as well as 
several epimers was reported by Ikota and coworkers. 88 This synthesis 
exploits the chirality of an amino acid derivative to produce 2. and some 
epimers, although in somewhat poor overall yields. The biosynthesis of 
swainsonine by Astragalus oxyphysus has been studied and shown to 
proceed via a pathway similar to that of production of .2. in the fungus 
Rhizoctonia leguminicola. Both syntheses are accompanied by production 
of 1-hydroxyindolizidine as well as 1,2-dihydroxyindolizidine. 89 A recent 
report has included the syntheses of not only swainsonine, but also some 
12 
related ring contracted pyrrolizidines from mannose derived starting 
materials.90 One additional report employs an intramolecular 1,3-dipolar 
cycloaddition of an olefinic azide as the key step in the preparation of .2 
from an erythrose derivative.91 
Several reports provide for syntheses of stereoisomers of 
swainsonine. Takaya et al.92 report the syntheses of 2,8-di-epi-swainsonine 
and 8-epi-swainsonine from D-glucose, by a one-step double cyclization 
process similar to that devised by Hashimoto. 87 The yields of this route 
were very poor, however, producing the isomers in 1.5% and 0.2%, 
respectively. Suami et al.93 synthesized 8-epi-swainsonine and 1,8-di-epi-
swainsonine from glucose derivatives following an analogous route as that 
used in the swainsonine synthesis. The yields of these isomers were 
somewhat higher at 4.3% and 3.2%, respectively. The synthesis of 8a-epi-
swainsonine by the same group via an azido-sugar prepared from glucose 
was reported shortly thereafter.94 The 2,8a- and 8,8a-swainsonine epimers 
also have been synthesized by a similar route.95 The synthesis of several 
polyhydroxy glycosidase inhibitors, including 8-epi-swainsonine, from a 
common glucose derived intermediate has appeared in a recent report. 96 In 
a similar pathway to that used in the synthesis of swainsonine, Ikota and 
Hanaki have prepared 1-epi-swainsonine and 1,8-di-epi-swainsonine from 
an amino acid derivative.97 Finally, the 8-, 8a-, and 8,8a-di-epimers of 
swainsonine have been synthesized by Kim and Cha in divergent syntheses 
from the same erythrose derivative utilized in that group's synthesis of 
swainsonine. 98 
13 
( + )-Castanospermine (l) has been the subject of a large body of 
synthetic work. Ganem and co-workers have reported two enantiospecific 
syntheses of J. from glucose derivatives, the second of which provides ( + )-
castanospermine in a very efficient 19% overall yield.99,100 Hashimoto et 
al. prepared J. employing an analogous route as that utilized in their 
synthesis of swainsonine92 starting with D-mannose.101 In a very extensive 
study of the synthetic utility of "naked sugars", 7-oxanorborn-5-en-2-yl 
derivatives, Vogel and co-workers synthesized (±)-castanospermine, 102 6-
deoxy derivatives, 103 and several other biologically interesting 
molecules. 104 The enantiospecific syntheses of (-)-swainsonine (Z) and 
( + )-castanospermine (l) have been effected via the corresponding 
hydroxylactams derived from monosaccharide lactones. 105 A relatively 
short (10 step) enantioselective synthesis of J. from a glucuronolactone 
derivative has also been reported. 106 Finally, a chemoenzymatic route to J. 
has been reported, employing microbial lipases in the preparation of a 
chiral pyrrolidine starting material. 107 
The syntheses of several analogues of J. have been reported. 1-
deoxy-castanospermine has been prepared. 108•109 The natural product that 
is present in smaller quantities in the natural source, 6-epi-
castanospermine, has been synthesized along with 1,6-di-epi-
castanospermine and their enantiomers, and the activity against 
amyloglucosidase studied. 110 The results show that only the natural 
product is active in inhibition of this enzyme, although other enzymes were 
not studied. The natural product has been isolated in sufficient quantity to 
allow for studies on the selective acy lation of ( + )-castanospermine by 
enzymes, 111 as well as through traditional chemical transformations. 112 
Finally, 6-acetamido-6-deoxy-J. has been prepared and shown to be a 
potent inhibitor of ~-N-acetylglucosaminidases, enzymes which have 
possible implications in tumor metastasis.113 
14 
Racemic slaframine ~) was first synthesized in 1970 from 2-bromo-
5-nitropyridine. 114 This investigation also included the preparation of an 
isomeric compound, the structure of which had incorrectly been assigned 
to slaframine, synthetically establishing the true structure of~- Gensler 
and Hu effected stereoselective synthesis of~ starting with a glutamic acid 
derivative.115 Both of these synthetic strategies were highlighted by 
Dieckmann conditions to effect second ring cyclization. More recently, 
Weinreb and co-workers have utilized an intramolecular imino Diels-Alder 
approach in the preparation of slaframine, a method that simultaneously 
produced 1-epi-slaframine.116 Harris and Schneider reported an efficient 
stereoselective synthesis of~ providing an overall yield of 12 % from a 
picolinic acid derivative. 117 The same group also later reported an 
extensive study of the biosynthesis of slaframine and swainsonine from 1-
hydroxyindolizidine.118 The reaction of potassium thalidomide and 
substituted cyclopropylphosphonium salts has been used as the key step in 
the preparation of racemic ~ as well as racemic 6-epi-slaframine.119 
Shono and co-workers have applied anodic oxidation to a lysine 
derivative120 to supply an intermediate that appears in the aforementioned 
synthesis of slaframine by Schneider and Harris, providing a formal 
15 
synthesis of i. Finally, in a very recent report, the reductive cyclization 
of azido epoxides accomplished cyclization of both rings of the bicyclic 
system in one step, and was employed in the first preparation of optically 
pure (-)-slaframine and (-)-1,8a-di-epi-slaframine. 121 
Syntheses of hydroxyindolizidines related to Z, J, and i also have 
been accomplished. The four possible stereo isomers of 1-
hydroxyindolizidine have been synthesized in order to assist the study of 
the biosynthesis of swainsonine (Z) and slaframine (4). 122 The preparation 
of cis-1-hydroxyindolizidine has been reported, 123 and the enantiospecific 
preparation of ( + )-(1 S,8aS)-1-hydroxyindolizidine as described 
previously. 63 Another biologically important analogue, 1,2-
dihydroxyindolizidine, is cited as a precursor in the biosynthesis of 
swainsonine in the fungus Rhizoctonia leguminicola. This product has been 
synthesized, both chemically124 and biologically, 125 and studied as a 
possible inhibitor of glucosidases. Although enzyme inhibition studies 
were not extensive, the data suggested that the weak inhibition of 
glucosidases by this compound indicated that the presence of a hydroxy-
functionality at the 8-position was necessary for potent activity. In one 
final report, 6, 7-dihydroxyindolizidine and 6,7 ,8-trihydroxyindolizidine 
were synthesized and tested for enzyme inhibition. The results showed both 
compounds to be very weak and non-selective inhibitors, also suggesting 
that substitution at the I -position is necessary for potency and selectivity of 
these compounds in the inhibition of glucosidases.126 
16 
Some related polyhydroxy monocyclic heterocycles such as 
piperidines (nojirimycin and analogues)127-130 and pyrrolidines, 131 -133 and 
carbocycles134 are potent anti-glycosidases. Polyhydroxypyrrolizidine 
alkaloids also have been the subject of recent investigations.135•136 Studies 
have been undertaken to decipher the relationship between structure and 
biological activity of these compounds in order to design optimum 
therapeutic action.137•138 Much work remains to be done in this area of 
research. 
Monomorine (S.) also has been the focus of a large amount of 
synthetic work. Oliver and Sonnet synthesized four possible stereoisomers 
of monomorine from 2,6-lutidine in order to unambiguously assign the 
structure of the natural product, (+)-monomorine, as 3R,5S,8aS.139•140 
This synthetic strategy also was used to decipher 13C NMR assignments of 
indolizidines.141 The stereoselective preparation of S. from a substituted 
pyrroline and 1,4-dibromopentane has been reported by Macdonald. 142 
Stevens and Lee have employed reductive amination conditions for the 
formation of ( + )-monomorine.143 The first enantiospecific preparation of 
(-)-S. was conducted in 1985 establishing the configuration of the natural 
product as ( + )-monomorine.144 Further stereoselective routes to S. have 
been effected from a hetero Diels-Alder intermediate145 and through a-
alkynylation of a 1-acylpyridinium salt. 146 Another enantioselective 
synthesis starting from a tartrate derivative has provided ( + )-monomorine, 
the first enantiospecific preparation of the natural product. 147 Racemic S. 
was prepared during the exploration of the utility of rhodium(II)-acetate 
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catalyzed decomposition of an intermediate diazo-compound, 148 and during 
method development for the preparation of ro-methyl lactams via reductive 
cyclizations of oxime intermediates. 149 Two very recent enantioselective 
syntheses were successful using asymmetric cleavage of a cyclic ketone150 
and asymmetric 1,3-dipolar nitrone cycloaddition. 151 
Far fewer syntheses of gephyrotoxin 223AB (2) have been 
completed, although the alkyl-indolizidines have received much synthetic 
interest. There are four stereoselective syntheses of 2. reported through 
1990. Of these, the methods of Kibayashi and co-workers152,153 and 
Stevens and Lee154 parallel those reported for the synthesis of S,. One 
additional synthesis of gephyrotoxin 223AB used a highly stereoselective 
radical cyclization. 155 
The pumiliotoxins are related dendrobatid alkaloids that consist of a 
large number of indolizidine structures. The indolizidines in this class are 
generally much more complex and will not be covered here. Other simple 
dendrobatid indolizidines have been isolated and the structures determined. 
These have been assigned numbers corresponding to their mass spectral 
parent ion peak and a few syntheses of these compounds have appeared in 
the recent literature. The 1,3-dipolar nitrone cycloaddition methodology 
has been applied to the preparation of indolizidines 167B Wl), 205A (11), 
and 207 A (ll), 156 and the enantioselective synthesis of (-)-209B (l.J.). 157 
The alkylation of a common intermediate, an amino nitrile, was used to 
provide both indolizidine 167B and 209D (li). 158 
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Svnthetic Approach- Historical -
Previous experimentation in our laboratory showed that the dianion 
of 4-(phenylsulfonyl)-butanoic acid ( 4-PSBA) U.S.) can be added to 
carbonyl compounds followed by subsequent cyclization to provide a very 
efficient one-pot procedure for the synthesis of lactones.159 (Scheme I) 
0 
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Extension of this methodology to the preparation of four-carbon 
homologated carbonyls provided an easily accessible alternative to Wittig 
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and Reformatsky transformations, 160 and has been incorporated into the 
synthesis of a pheromone natural product. 161 
Broadening the scope of this synthetic strategy to the preparation of 
nitrogen heterocycles requires reaction with nitrogen-containing 
electrophiles isoelectronic with carbonyls, namely, imines. 
The addition of carbon-based nucleophiles to imines has been well 
documented, yet underused in actual synthetic pathways. The chemistry of 
imines has been reviewed, 162 as has the most common nucleophilic 
addition reaction; lithium ester enolate-imine condensation (Reformatsky-
type).163 This condensation has been used in the preparation of a wide 
variety of ~-lactams. Additional common reactions of imines with 
nucleophiles include reaction with Grignard reagents to give substituted 
amines164·165 and Lewis acid-catalyzed addition of silyl ketene acetals to 
give ~-lactams. 166 Other imine reactions of interest include the imino 
Diels-Alder reaction employing activated imines and dienes.167 Lithiated 
nucleophiles other than an ester enolate also have been used to provide 
substituted amines that are often formed in asymmetric additions or with 
chiral auxiliaries.168,169 Yamamoto and co-workers have conducted a great 
deal of research on the Cram selectivity of the additions of organometallic 
reagents to imines, and showed that the Lewis acid necessary for the 
activation of the imine must be syn to the side chain R group.170-173 
Examination of the possible transition states provides a rationale for the 
observed erythro predominance in the case of relatively unhindered 
nucleophiles and imines. However, the diastereoselectivity of imine 
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additions was determined to be very dependent upon both the nitrogen R 
group and the side chain substitution, in contrast to the corresponding 
carbonyl additions. Only one report of the addition of dianions to imines 
has appeared, again employing a lithium ester enolate to provide substituted 
amines. 174 
In preliminary investigations, a variety of imines were prepared 
through standard condensation reactions of aldehydes and ketones with 
primary amines, and purified by distillation. These imines were subjected 
to addition reactions with the dianion of 4-PSBA followed by cyclization 
with trifluoroacetic anhydride to provide 2-piperidones in an efficient two-
step procedure. 175 (Scheme II) 
SCHEME II 
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n-Pr n-Pr H 70 
CH3 PhCH=CH H 82 
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This investigation established the necessity of Lewis acid activation 
of the imines in order for addition to occur. Boron trifluoride etherate 
was chosen as the Lewis acid for this transformation over several other 
possibilities (ZnBri, MgC!i, AlCl3, SnCl4, Ti(O-ipr)4), all of which were 
shown to be inferior for obtaining the desired addition product. This 
synthetic method has broad application as there exists a multitude of 
biologically important piperidine-containing natural products. 
Chapter 2 
Results and Discussion 
The initial approach to the construction of indolizidines envisioned 
the addition of the dianion of 4-(phenylsulfonyl)-butanoic acid (4-PSBA) 
(ll) to appropriately activated cyclic imines (Scheme III). This strategy 
would effectively provide the indolizidine skeleton in one step from the 
imines. 
0 
ll 18 R= SCH3 
12. R=OCH3 
Scheme III 
1) activate imine 
2) cyclize 
0 
Our initial experiments concerned the addition of the dianion of 4-
PSBA to cyclic imines with leaving groups (R) situated at the 2-position. 
This approach could provide, after subsequent structure manipulation, 
indolizidines that are unsubstituted at the Sa-position, the most common 
occurrence in simple natural products of this class. The two cyclic imines 
that were used in this study were the iminothioether 18 (R = SCH3) and the 
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Iactim ether 19 (R = OCH3). The iminothioether was prepared via 
alkylation of the corresponding thioamide (2-pyrrolidone, Lawesson's 
reagent, toluene, reflux, 90%),176 followed by free base liberation (50% 
KOH, diethyl ether extraction, 63%).177 Boron trifluoride etherate 
activation of this product, followed by dianion addition-cyclization yielded 
primarily unreacted starting materials and a small amount of an addition 
product ( <2% ). This product exhibited spectra indicative of elimination 
product Zil,. The major difficulties in the proper isolation of product most 
probably lies in the need for very pure starting materials (the 
iminothioether is very volatile and thus difficult to distill free from 
solvent) as well as problematic product purification. The crude reaction 
mixture was highly colored necessitating chromatographic purification. 
The very high polarity of the desired product causes some difficulties in 
elution with separation on silica columns. The enamine-type structure 20 
would be expected to be sensitive to acids and nucleophiles complicating 
isolation. 
0 
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In 1984, Smith and co-workers reported the addition of 
organolithium nucleophiles to lactim ethers to provide 2-alkylated cyclic 
imines in moderate to good yields. 178 Thus, lactim ether 12. was prepared 
from 2-pyrrolidone (dimethyl sulfate, benzene). 179 In our hands, however, 
adequately pure lactim ether could not be isolated. Fractional distillation 
of the lactim ether (bp 118-120° C) from solvent was difficult. 
Additionally, it has recently been reported that upon heating, the lactim 
ether rearranges to N-methyl-2-pyrrolidinone.180 Thus, we turned our 
attention to the addition of the dianion of 4-PSBA to alkyl-substituted 
cyclic imines (Scheme III, R=alkyl). 
A search of the literature for methods for the preparation of cyclic 
imines revealed that rapid synthetic entry into these compounds needed 
augmentation. Bonnet et al.181 reported the conversion of y-nitrocarbonyls 
to cyclic alkyl imines. This strategy involves protection of the carbonyl as 
the cyclic ketal, followed by catalytic hydrogenation of the nitro group to 
the amine. Subsequent deprotection of the carbonyl results in spontaneous 
ring closure to provide the cyclic imines. Kloetzel 182 showed that direct 
hydrogenation of y-nitrocarbonyls resulted in obtaining a mixture of both 
the desired cyclic imine and the overreduced cyclic amine, the latter being 
the predominant species. The conditions employed in this latter report 
were severe (very high H2 pressures and temperatures). As the nitro 
group is especially susceptible to reduction by catalytic hydrogenation, we 
theorized that it might be possible to chemoselectively reduce the nitro-
moiety in the presence of the unprotected carbonyl group. 
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We obtained the cyclic imines in good yields from y-nitrocarbonyl 
compounds (obtained from a Michael addition of nitroalkanes to a,l3-
unsaturated ketones) using catalytic hydrogenation (H2 pressures of less 
than 20 psi; Scheme IV). The imines were identified by a strong 
absorption in the IR at 1620 cm-1 (C=N). Further synthetic verification of 
the products included preparation of 2,4,4-trimethyl-~Lpyrroline (ll, 
R1 ,R2,R3=CH3) by the method of Bonnet et al., as well as reduction of the 
product with lithium aluminum hydride to yield 2,4,4-trimethylpyrrolidine 
(identified by NMR and IR). 
Scheme IV 
+ Base 
ll 
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The addition of the dianion of 4-PSBA to alkyl imines l1 was, 
unfortunately, largely unsuccessful. In only one instance, the case of 2,4,4-
trimethy l-~ Lpyrroline, was a product obtained that provided reasonable 
spectral evidence of desired lactam formation, although in very poor yields 
(approx. 10% ). Further analysis of the spectral and analytical data for this 
adduct show that it may be the uncyclized amino acid addition product. 
Possible reasons for the inability to obtain the desired bicyclic lactams 
from this reaction include the previously documented trimerization of the 
cyclic imines,183 the potential enamine tautomerization, and the steric 
crowding that the presence of the alkyl substituent at the unsaturation site 
creates. Indolizidine natural products are primarily unsubstituted at the 8a 
position, requiring cyclic imine precursors that possess only a hydrogen at 
the 2-position. In light of the difficulties in obtaining cyclic imines that are 
unsubstituted at the 2-position due to the trimerization phenomena,3 as well 
as the previously noted complications in obtaining these addition products, 
a different approach was devised to obtain the bicyclic indolizidine system. 
This synthetic strategy takes advantage of the previously developed 
methodology of the addition of the dianion of 4-PSBA to Lewis acid 
activated acyclic imines (see Chapter 1, pages 15-17).175 The six-
membered ring of the bicyclic system is formed first through the dianion 
addition-cyclization procedure. Then closure of the five-membered ring 
follows facilitated by appropriate side chain substitution of the imine 
starting material. The requisite imine precursor for these transformations 
contains a four carbon side chain with a terminal protected alcohol. This 
imine was derived from 1,4-butanediol as shown in Scheme V. 
~~,..OH 
HO'~~ 
Scheme V 
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First, 1,4-butanediol was monoprotected as the benzyl ether. This 
was accomplished using a large excess (5-1 Ox) of the diol in reaction with 
base and benzyl bromide.184 The unreacted diol was removed in the 
aqueous extractions to provide clean monoprotected product 24 in very 
high yield (95% based on benzyl bromide). The use of a large excess of 
the diol is not a concern in this transformation due to the relative inexpense 
of this reagent as well as the ease of product purification. The unprotected 
terminal hydroxy functionality was oxidized to the aldehyde with 
pyridinium chlorochromate (PCC). This reaction proceeded in somewhat 
low yields, perhaps owing to the difficulties encountered in isolating ~ 
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from the "tar" produced in PCC oxidations. It was noted that distillation of 
the aldehyde ~ (80°C, 0.3mm) resulted in lower yields (57%) than did 
column purification (67-71 %) presumably due to thermal degradation of 
the ZS,. Swem185 and Jones 186 oxidation conditions did not offer 
significantly better yields (50-70% ). The aldehyde obtained is a known 
material, 1s7 although experimental procedures for the preparation of this 
compound have not yet been published. Finally, imine Zn was prepared by 
condensation of the aldehyde with benzylamine in very high yield (93-
95% ). Product li is relatively unstable, being readily hydrolyzed back to 
the aldehyde in the presence of water. Thus, the dianion addition reactions 
were generally performed within a few hours of imine formation. 
The dianion addition-cyclization reaction (lactam formation) proved 
to be very sensitive to the conditions employed and required extensive 
experimentation. The instability of the imines necessitated distillation of 
boron trifluoride etherate immediately prior to use. It also was noted that 
the color of the dianion solution was discharged instantaneously upon 
addition of the imine complex. If reaction was allowed to continue for 
longer than 5 minutes before addition of trifluoroacetic anhydride 
(TFAA), the reaction yields were much lower. This is probably due to 
relocation of the resultant dianion to a more stable dianion wherein the 
second anionic site is alpha to the sulfonyl carbon as opposed to the initially 
generated nitrogen anion. The combination of these two precautions 
increased the yield of lactam formation from the initially obtained values 
of 20-40% to a consistent 76% (Scheme VI). The major side-product 
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appears to be the N-benzyl amide of 4-PSBA. This product probably arises 
from unreacted benzylamine present in the imine solution. 
0 
1.S. 
Scheme VI 
0 
27a&b 
The lactam 27 possesses two chiral centers providing a mixture of 
two sets of enantiomers 27a & .b,. These products are obtained in 
approximately 1 :2 ratio (denoted fast 27a and slow 27b, respectively, due 
to their normal phase chromatographic elution order). The spectra of 
these products were extremely complex requiring lH-lH COSY and 1H-13C 
COSY experiments to make spectral assignments. Deprotection of the 
terminal hydroxy functionality was carried out by hydrogenolysis under 
acidic conditions (10% Pd/C, trifluoroacetic acid) to provide 28a & .b. 
whose NMR spectra were sufficiently simplified (although it is still 
essential that 2-D NMR experiments be done) to allow configurational 
assignments. The predominant isomeric mixture (slow band 28b) has been 
assigned the conformations shown in Figure 2, where the phenylsulfonyl 
group and alkyl side-chain are in tum situated axial and equatorial (cis). 
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The other enantiomeric mixture (fast band ZB.a) is then the configuration 
where these two groups are on opposite sides (diaxial and diequatorial) of 
the ring (trans). 
Figure 2 
This assignment is based on the lH NMR coupling constants (J) of Ha 
and Hb and examination of models and molecular modelling calculations. 
These configurations are also in accordance with the facial selectivity 
observed by Yamamoto et al. in the addition of organometallics to 
imines142 (Scheme VII). When the two R groups are cis, the angle 0 
between Ha and Hb is approximately 60° in both R,S and S,R enantiomers. 
Thus, the enantiomeric mix would exhibit a relatively simple spectrum 
with a JHaHb of approximately 2.0 Hz. This J value becomes 2.5 Hz for a 
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Karplus curve shifted for electronegative substituents(such as the 
phenylsulfonyl group ). 188 In contrast, the diequatorial and diaxial 
enantiomeric mixture (S,S and R,R) provides two 0 values of 60° and 180°, 
giving rise to two coupling constants of 2 Hz and 9 .5 Hz, respectively, 
creating a much more complex spectrum. Indeed, in the slow lactam mix, 
a lHaHb of 2.5 Hz was observed, while the fast band spectrum was too 
complex to discern a single coupling constant for JHaHb, and peak overlap 
led to difficulties in assignment. These correlations lead to the assignments 
of the enantiomeric mixes as shown above. 
L 
I 
R M-L , .......... ,, 
0 c=N --J:..-; I 
H R' 
Scheme VII 
CH3 QH3 R~+RY" 
NHR' NHR' 
syn (major) anti (minor) 
Y amamoto's model 
Dianion addition model 
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The transformation of the diastereomeric lactams obtained from the 
dianion addition-cyclization sequence into the desired indolizidines is 
outlined in Scheme VIII. The de-0-benzylated lactam ZB. was first reduced 
to the corresponding piperidine with three equivalents of borane-
tetrahydrofuran complex (BH3·THF). The terminal hydroxy group was 
then converted to a mesyl (methanesulfonyl) leaving group by reaction 
with either methanesulfonyl chloride (MsCl) or methanesulfonyl anhydride 
(Ms20). This reaction proceeded with immediate nucleophilic 
displacement of the mesyl group to give the quatemized ammonium salt 
Ji!. This was liberated as the free base by removal of the N-benzyl group 
via hydrogenolysis over Pearlman's catalyst (20% palladium hydroxide on 
carbon). 189 The resulting 8-(phenylsulfonyl)-indolizidines J1 from both 
enantiomeric mixtures were white crystalline products. However, these 
products are rapidly oxidized in air to form N-oxides, which cause large 
errors in the combustion analyses. The presence of this impurity was, 
fortunately, small enough to allow verification of product formation via 
high resolution mass spectrometry (HRMS). Conversion to the well 
characterized 8-coniceine was effected by desulfonylation with sodium 
amalgam (Na/Hg)190 to provide indistinguishable products from fast and 
slow bands. 
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These products exhibited spectra ( 1 H and 13C) that were identical to 
authentic B-coniceine 1. B-Coniceine was prepared in an alternate route 
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employing the Hofmann-Loffler cyclization of bromoconiine Jl in order 
to compare and validate the physical properties and spectral data of our 
synthetic product (Scheme IX). 
The sequence consists of nine steps and proceeds with an overall 
yield of 15.4%, comparing favorably with many of the synthetic methods 
previously reported for 1. 
Scheme IX 
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With the methodology in hand to synthesize indolizidines from 
imines, we turned our attention to the preparation of a more complex 
indolizidine natural product. One of the lesser structurally demanding of 
these is 1-hydroxyindolizidine (8.), which as mentioned previously, is an 
important intermediate in the biosynthesis of swainsonine and slaframine. 
The synthesis of this compound requires the availability of an imine with 
an alpha-hydroxy functionality. The synthesis of this imine from S-malic 
acid is outlined in Scheme X. 
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Toe synthesis of the benzyloxymethoxy lactone lZ is a procedure 
developed by Still et al. as part of a synthesis of monensin. 191 (S)-(-)-malic 
acid was first protected as the five-membered acetonide J.4 (2,2-
dimethoxypropane, p-toluenesulfonic acid). It should be noted here that 
this acetonide is the kinetic product and the thermodynamically more stable 
6-membered ring was formed if the reaction was allowed to continue. 
The carboxylic acid was then reduced to the alcohol with BH3·THF. This 
unstable product was rapidly converted to 3-hydroxybutyrolactone upon 
heating with acid (p-TsOH). In this process, deprotection of the acetonide 
led to intramolecular esterification (lactonization) to afford ~- The 
remaining free hydroxy moiety was protected as the benzyloxymethyl 
(BOM) ether to provide the known lactone J1. in 33% overall yield (52% 
reported by Still et al.). Reduction of the ester with diisobutyl aluminum 
hydride (DIBAl-H) provided the lactol that exists in equilibrium with the 
open-chain hydroxy aldehyde form J2,. The NMR spectra of this 
compound is further complicated by the presence of two lactols (a second 
chiral center is created in the reduction) resembling the a and~ anomers 
of the furanose forms of sugars. Indeed, the 13C spectrum contains signals 
for 12 non-aromatic carbons, when only 6 signals for la are expected. 
This fits nicely with the model of 13C spectra for sugars where the 
anomers can be distinguished.192 A study of the 1 H NMR and IR spectra of 
la in several different solvents was undertaken in order to determine the 
optimum solvent for obtaining the desired aldehyde form. In all solvents 
tried (CD3CN, diethyl ether, acetone, methanol, THF, CDCl3) the lactol 
predominates, with only THF showing signs of the presence of aldehyde. 
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This information was used to advantage in an optimization of the yield for 
the DIBAl-H reduction. Using diethyl ether rather than THF as the 
solvent, the overreduction of the lactone to the diol was decreased. Next, 
protection of the terminal hydroxy functionality of the open-chain aldehyde 
form was attempted. Several selective protecting groups were examined. 
The tert-butyldimethylsilyl (TBDMS) ether was prepared, yet the lactol 
was preferentially protected to yield a 3:1 ratio of TBDMS-lactol and 
TBDMS-aldehyde, respectively. The diphenylmethylsilyl ether also was 
prepared, yielding only protected lactol. One final silyl ether, the tert-
butyldiphenylsilyl (TBDPS) ether provided primarily the desired aldehyde. 
This aldehyde was converted to the imine by condensation with 
benzylamine. Reaction of the activated imine with the dianion of 4-PSBA 
followed by attempted cyclization resulted in an addition product that was 
uncyclized. This difficulty arises presumably because of the extreme 
bulkiness of the side chain with both BOM ether and TBDPS ether 
appendages. In continuation of the protecting group strategy, benzyl ether 
preparation yielded only protected lactol and the attempted protection as 
the triphenylmethyl(trityl) ether resulted in no reaction. At this juncture, 
it was decided that the direct condensation of the lactol J.B. with 
benzylamine to effectively trap the aldehyde would provide the desired 
imine product, albeit with a terminal unprotected hydroxy functionality. 
This approach did provide the imine, although the product was very 
unstable and not amenable to subsequent alcohol protection steps. 
Attempted protection as the TBDMS and benzyl ethers resulted in some 
product formation although workup procedures were accompanied by 
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significant hydrolysis of the imine. The imine product .il was not easily 
characterized, perhaps due to the presence of the hemi-aminal ~ formed 
from cyclization of the hydroxy group onto the imine. Since these 
products are in equilibrium favoring the cyclic hemi-aminal, they are not 
readilY separated and characterized. Thus, the dianion addition reaction 
was performed directly on the 40/41 product mixture in hopes that 
deprotonation of .iQ would lead to formation of the desired alkoxy-imine 
in sitU (Scheme XI). 
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The diastereomeric chiral lactams 42 ( denoted as fast and slow based 
on weir normal phase chromatographic behavior) were obtained in low 
yieldS (29% purified, 54% maximum based on 4-PSBA recovery) again in 
a 2: 1 (slow/fast) ratio as in the case of the achiral lactam. The low yield is 
presumably due to impure starting imine, with the equilibrium still 
favoring the hemiaminal form. The addition-cyclization reaction required 
two equivalents of the dianion; one to deprotonate the unprotected terminal 
hydroxy functionality. The second equivalent of the dianion is delivered to 
the jflline. The use of two equivalents of 4-PSBA was not of great concern 
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because greater than 95% of the unreacted acid could be recovered from 
the basic, aqueous washings performed in the normal workup procedure. 
Toe reaction products were carefully separated and analyzed to reveal that 
only two of the four possible diastereomers of the lactam were formed. 
The remainder of the reaction products appeared to correspond to the N -
benzyl amide of 4-PSBA and the product of addition of the dianion of 4-
PSBA to unreacted lactol (the lactone). The enhanced diastereoselection 
observed in this reaction (the isolation of only two of the four possible 
diastereomers) is presumably due to the additional bulk of the a-
benzyloxymethoxy ether moiety. Invoking a six-membered transition state 
model as before, the steric bulk of the imine side-chain precludes it from 
being axial since 1,3-diaxial interactions would prohibit facile approach of 
the nucleophile. This model accounts for the observed products, although 
examination of Drieding stereomodels suggests that the opposite 
stereochemistry for the bridgehead proton would result from attack upon 
the imine at the face opposite the protected hydroxy group. The relative 
cis/trans orientation of the imine during attack is not known and is of 
importance in the inclusion of stereomodels. 
Conversion of .il into the desired 1-hydroxyindolizidine R is 
analogous to the achiral 8-coniceine synthesis (Scheme XII). 
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The lactams were first reduced to the corresponding piperidines .iJ 
with borane-THF. The piperidines were converted to the mesylates, 
resulting in spontaneous quaternization to the bicyclic indolizidine mesylate 
~- Hydrogenolysis with Pearlman's catalyst provided the BOM-protected 
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I-hydroxy-8-(phenylsulfonyl)-indolizidine .iS,. It was noted that if the 
hydrogenolysis was carried out under slightly acidic conditions (10 µL · 
TFA), cleavage of the BOM protecting group could be achieved 
concurrently with N-benzyl ether cleavage. This allows for the synthetic 
route to the chiral 1-hydroxyindolizidine to be shorter in actual number of 
steps than the achiral indolizidine. The final step in the synthesis was the 
desulfonylation with sodium amalgam to provide 1-hydroxyindolizidine (a) 
from both fast and slow bands. This sequence formally consists of seven 
steps (from Still's intermediate) and proceeds in approximately 3% overall 
yield. The two 1-hydroxyindolizidines obtained exhibited optical rotations 
that indicated they were the same product. The rotations are very close to 
that reported for (+)-(IS, 8aS)-1-hydroxyindolizidine, a 0 22=16.4(0.28, 
CDCl3) and 18.1(0.42, CDCl3), lit. a 0 22=20.2°(1.03, EtOH),64 leading to 
the conclusion that this route is enantioselective. Throughout the synthetic 
transformations, the products from fast and slow bands have exhibited 
markedly different optical rotations and have been chromatographically 
separable. This indicates that the two predominant products are 
diastereomers at the phenylsulfonyl substituted carbon, and that upon 
desulfonylation, this difference is removed to provide the same 1-
hydroxyindolizidine product. The slight variations in the rotation values 
can be accounted for in the concentration and solvent differences. There 
was insufficient material to obtain rotation data at higher concentrations 
and the volatility of the product precluded the use of ethanol. The 
enantioselectivity has been accounted for in the above representations of the 
facial selectivity of the addition reaction. Chiral resolution of the products 
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was facilitated by derivatization with (S)-1-napthylethyl isocyanate. HPLC 
analysis (D-phenylglycine, elution with 70:30 hexane/isopropanol) showed 
the 1-hydroxyindolizidines to be >99% optically pure and 
chromatographically identical. 
Chapter 3 
Conclusions 
This investigation showed that the "remote" dianion addition-
cyclization procedure can be extended to include the diastereoselective 
preparation of indolizidines from imines. Moreover, this synthetic route 
has proven to be an enantioselective method for the preparation of chiral 
indolizidine alkaloids when applied to imines with chiral appendages. 
One of the most important aspects of this research is the 
preparation of lactams from functionally substituted imines. A wide 
variety of indolizidine alkaloid natural products and analogues can be 
readily accessed from these intermediates (Scheme XIII). 
Thus, the goal of providing a versatile synthetic strategy for the 
preparation of indolizidine alkaloids and analogues has been achieved. 
Additionally, we have provided one of the very few enantioselective 
routes for the formation of these compounds. Future studies in this 
project should include the re-analysis of the application of the dianion 
addition-cyclization methodology to cyclic imines, extension to alkyl 
substituted indolizidines (e.g. gephyrotoxins), and preparation of 
polyhydroxy indolizidines. 
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Chapter 4 
Experimental 
General Methods. Melting points were determined on a Mel-Temp 
melting point apparatus and are uncorrected. NMR spectra were recorded 
emplo a Varian VXR-300 spectrometer. lH NMR spectra were taken in 
deuterated chloroform (CDCb) at 300 MHz. 13C NMR spectra were taken 
at 75 MHz. 13C assignments were made with the aid of DEPT experiments 
(see appendix). 2-D HOMCOR experimental results are also presented in 
the appendix. Infrared data were obtained in CDCb on a Perkin Elmer 
1400 spectrometer. Optical rotations were measured on a Perkin Elmer 
241 Polarimeter using a 100 mm path length 1 mL quartz cell. 
Analytical thin layer chromatography (TLC) was conducted with 
aluminum-backed silica plates (E. Merck). Visualization was accomplished 
with an ultraviolet lamp and/or anisaldehyde stain (2% o-anisaldehyde in 
95:4: 1 absolute ethanol-concentrated sulfuric acid-glacial acetic acid) with 
heating and/or iron(III) chloride-hydroxylamine stain and/or ninhydrin. 
Flash chromatography was done on Kieselgel 60, 230-400 mesh (E. 
Merck). Florisil (100-200 mesh; Fisher) was used where noted. 
All solvents and reagents were purified when necessary according to 
standard literature methods. Air- or water-sensitive reactions were 
conducted under a positive argon atmosphere utilizing standard techniques. 
Hydrogenolyses were conducted either with doubled balloon pressures (10-
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20 psi H2) or in a Parr shaker (>20 psi H2). Most reagents were purchased 
from Aldrich Chemical Co.(Milwaukee, WI); S-malic acid was obtained 
from Research Organics, Inc.(Cleveland, OH). 
1. O-benzyl 1,4-butanediol, .li,. 1,4-butanediol (20 g, 0.22 mol.) was 
stirred at ambient temperature with 12 g powdered KOH. Benzyl bromide 
(6.0 mL, 50.4 mmol) was added and after 2 h, 100 mL H2O was added. 
The reaction mixture was cooled and extracted thrice with diethyl ether. 
The combined organic layers were were dried over Na2SO4 and the solvent 
was removed in vacuo. Column chromatography (4:1 diethyl 
ether/petroleum ether) yielded 8.62 g of a clear oil (95% ). Rf= 0.34 
(diethyl ether) IR 3430 cm-1 (OH, broad). Anal. calcd for C11H16O2: C, 
73.30; H, 8.95. Found: C, 72.97; H, 9.08. lH NMR 1.68 (m, 4 H), 2.33 (s, 
1 H), 3.51 (t, 2 H, J = 5.8 Hz), 3.63 (t, 2 H, J = 6.0 Hz), 4.51 (s, 2 H), 7.30 
(m, 5 H). 13C NMR 26.60, 30.06, 62.62, 70.31, 73.01, 127.59, 127.65, 
128.36, 138.23. 
2. 4-(benzyloxy)-butanal, ZS,. Alcohol Zi.( 2.0 g, 11.1 mmol) was 
dissolved in 2 mL CH2Cl2 and added to a stirred mixture of 3.0 g 
pyridinium chlorochromate ( 13.9 mmol, 1.25 eq) in 200 mL CH2Cl2. 
After 1 h, the mixture was filtered and the solvent was removed in vacuo. 
The residue was dissolved in diethyl ether and extracted with saturated 
Na2CO3. The organic phase was dried over Na2SO4 and the solvent was 
removed in vacuo. Column chromatography (1:1 CH2Clifpetroleum ether) 
yielded 1.33 g (67%) as a colorless oil. Rf= 0.54 (diethyl ether). IR 1720 
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cm-1 (C=O, strong). 1H NMR 1.87 (m, 2 H), 2.47 (dt, 2 H, J = 1.6, 7.1 
Hz), 3.43 (t, 2 H, J = 6.1 Hz), 4.41 (s, 2 H), 7.20 (m, 5 H), 9.70 (t, 1 H, J = 
1.5 Hz). 13C NMR 22.57, 40.88, 69.12, 72.92, 127.56, 127.84, 128.28, 
128.34, 138.28, 202.06. 
3. N-benzylidene-4-(0-benzyl)-butanal, ,li. Aldehyde ll (1.33g, 
7 .5 mmol) was dissolved in approx. 1 mL toluene and was added to a 
stirring solution of benzylamine (0.80 g, 7.5 mmol) in 1 mL toluene. The 
mixture turned warm and became cloudy. After stirring at room 
temperature for 2 h, anhydrous diethyl ether (approx. 2 mL) was added 
and the organic phase was decanted and dried with BaO at O °C overnight. 
Following filtration and removal of solvent in vacuo, unreacted 
benzylamine and aldehyde were removed by heating at reduced pressure 
(50°C at 0.3mm) to yield 1.89 g (95%) of lightly yellow oil. This product 
was not stable and was used within hours of preparation without further 
purification. Rf= 0.45 (diethyl ether). IR 1660 cm-1 (C=N, strong). lH 
NMR 1.98 (quint, 2 H, J = 7.1 Hz), 2.47 (m, 2 H), 3.59 (t, 2 H, J = 6.4 Hz), 
4.56 (s, 2 H), 4.62 (s, 2 H), 7.33 (m, 10 H), 7.88 (m, 1 H). 13C NMR 
26.16, 32.79, 65.02, 69.60, 72.86, 126.85, 127.51, 127.57, 127.86, 128.25, 
128.33, 128.41, 165.61. 
4. 1-benzyl-5-(phenylsulfonyl)-6-[3-benzyloxypropyl]-2-
piperidinone, ll. Imine l.6. (1.72 g, 6.4 mmol) was dissolved in 5 mL 
THF. The mixture was cooled to -78 °C under argon and 1.0 mL boron 
trifluoride etherate (1.25 eq) was added. Concurrently, the dianion of 4-
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pSBA was generated: 4-PSBA (1.46 g, 6.4 mmol) was dissolved in 75 mL 
THF, cooled to -78 °C under argon, and 5.1 mL butyllithium (2.5 Min 
bexanes, 12.75 mmol) was added slowly. After 0.5 h, the activated imine 
solution was transferred via cannula to the dianion solution. The yellow 
color of the dianion solution quenched immediately, and within 5 minutes 
1.7 mL trifluoroacetic anhydride (TFAA, 12.0 mmol) was added. The 
solution was allowed to equilibrate slowly to ambient temperature followed 
by the addition of 50 mL ethyl acetate. The reaction mixture was extracted 
twice with saturated Na2CO3 with a subsequent brine wash. The organic 
phase was dried over Na2SO4, filtered, and the solvent was removed in 
vacuo. Flash chromatography (1: 1 ethyl acetate/CHCb) yielded products 
lliand 27b with Rf= 0.34, 0.28 (ethyl acetate) in approximately 1:2 
ratio, respectively. 2.56 g recovered (75.6%). HRMS m/z calcd for 
C2gH31NO4S 477.1974, found 477.1938. 
lli Fast band (Rf= 0.34) IR 1635 cm-1 (C=O, strong). lH NMR 
1.77 (m, 2 H), 2.09 (m, 2 H), 2.47 (m, 2 H), 2.66 (m, 1 H), 3.09 (m, 
2 H), 3.48 (t, 2 H, J = 6.1 Hz), 3.67 (m, 2 H), 4.50 (s, 2 H), 5.47 (d, 
1 H, J = 14.5 Hz), 7.46 (m, 15 H). 13C NMR 16.85, 27.42, 27.85, 
28.59, 50.73, 54.63, 63.25, 69.96, 73.13, 127.65, 127.75, 127.95, 
128.13, 128.33, 128.44, 128.77, 129.34, 129.41, 133.94, 136.62, 
169.04. (Some aromatic resonances unresolved). 
21b. Slow band (Rf= 0.28) IR 1638 cm-1 (C=O, strong). lH 
NMR 1.24 (m, 2 H), 1.57 (m, 1 H), 1.76 (m, 1 H), 2.27 (m, 3 H), 
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2.76 (m, 1 H), 3.19 (m, 3 H), 3.67 (dt, 1 H, J = 2.6, 9.7 Hz), 3.95 (d, 
1 H, J = 14.8 Hz), 4.38 (s, 2 H), 5.27 (d, 1 H, J = 14.7 Hz), 7.43 (m, 
15 H). 13C NMR 18.74, 25.28, 28.86, 30.42, 48.08, 53.35, 60.66, 
68.83, 73.04, 127.58, 127.64, 127.72, 128.10, 128.31, 128.43, 
128.57, 128.74, 129.14, 129.20, 129.27, 129.39, 133.89, 136.60, 
137.05, 138.12, 169.46. (Some aromatic resonances unresolved). 
5. l-benzyl-5-(phenylsulfonyl)-6-[3-hydroxypropyl]-2-
piperidinone, .2.B,. Lactam Z1 (0.6 g, 1.26 mmol) was dissolved in 
approximately 2 mL THF and methanol was added until solution became 
just cloudy (approx. 4 mL). The reaction vessel (2-neck round bottom 
flask) was flushed with argon, 60 mg 10% Pd/C was added followed by 10 
µL trifluroacetic acid. A doubled balloon charged with H2 was connected 
to the reaction flask. Hydrogen was introduced by mild evacuation of the 
flask (aspirator vacuum) followed by opening of the H2 balloon inlet. The 
mixture was stirred at ambient temperature under H2 ( <20 psi) overnight. 
Filtration and subsequent solvent removal in vacuo yielded 0.396 g (82%) 
as a clear oil. Anal. calcd for C21H25NO4S: C, 65.09; H, 6.50; N, 3.61. 
Found: C, 64.85; H, 6.39; N, 3.55. 
l£a Fast band Rf= 0.10 (ethyl acetate). IR 3400 cm- 1 (OH), 1638 
cm-1 (C=O). lH NMR 1.80 (m, 4 H), 2.05 (m, 1 H), 2.25 (m, 1 H), 
2.54 (m, 2 H), 2.73 (m, 1 H), 3.13 (m, 1 H), 3.71 (t, 2 H, J = 5.7 
Hz), 3.82 (m, 2 H), 5.49 (d, 1 H, J = 14.5 Hz), 7.20 (m, 2 H), 7.35 
(m, 3 H), 7.55(m, 2 H), 7.70(m, 3 H). 13C NMR 17.00, 27.58, 
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28.63, 30.13, 50.77, 54.47 (CH), 62.29, 63.12 (CH), 127.80, 128.25, 
128.28, 128.75, 128.76, 129.40, 134.05, 136.50, 137.88, 169.05. 
(Some aromatic resonances unresolved) . 
.2.8.b. Slow band Recrystallized in CH2Clzfhexane to provide white 
crystals. mp. 136-137°C. Rf= 0.08 (ethyl acetate). IR 3400 cm-1 
(OH), 1640 cm-1 (C=O). 1H NMR 1.09 (m, 1 H), 1.24 (m, 1 H), 
1.56 (m, 1 H), 1.73 (m, 1 H), 1.93 (s, 1 H), 2.26 (m, 3 H), 2.75 (m, 
1 H), 3.21 (dt, 1 H, J = 2.3, 6.1 Hz), 3.35 (m, 2 H), 3.67 (dt, 1 H, J = 
2.6, 9.4 Hz), 3.98 (d, 1 H, J = 14.7 Hz), 5.25 (d, 1 H, J = 14.7 Hz), 
7.42 (m, 10 H). 13C NMR 19.75, 27.79, 28.84, 30.13, 48.09, 53.29 
(CH), 60.70 (CH), 61.26, 127.67, 128.68, 128.69, 129.14, 129.28, 
133.95, 136.56, 169.55. (Some aromatic resonances unresolved). 
6. 2-(3-hydroxypropyl)-3-phenylsulfonyl-N-benzyl piperidine, 
.2,2. Piperidinone 2.8. (0.255 g, 0.66 mmol) was dissolved in 2 mL THF. 
The mixture was cooled to O °C and 2.0 mL BH3·THF (3.0 eq) was added. 
The reaction was allowed to equilibrate to ambient temperature and the 
excess borane was hydrolysed with 5 drops 5% NaOH. Subsequent 
partitioning between ethyl acetate and saturated Na2CO3 followed by 
drying the organic phase over Na2SO4 and removal of solvent in vacuo 
yielded a white foam, 0.212 g (86%). This product was purified by florisil 
chromatography (1:1 CH2Cb/diethyl ether) to give 0.155 g of a clear oil 
(63%). HRMS m/z calcd for C21H27NO3S 373.1712, found 373.1723. 
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l2,a Fast band Rf= 0.44 (ethyl acetate). lH NMR 1.52 (m, 1 H), 
1.79 (m, 4 H), 2.09 (m, 3 H), 2.60 (dd, 1 H, J = 4.3, 14.1 Hz), 2.90 
(dt, 1 H, J = 3.5, 13.8 Hz), 3.34 (m, 1 H), 3.61 (m, 4 H), 3.74 (d, 1 
H, J = 12.9 Hz), 3.84 (d, 1 H, J = 13.0 Hz), 7.33 (m, 5 H), 7.68 (m, 3 
H), 7.94 (m, 2 H). 13C NMR 20.02, 20.23, 23.45, 30.78, 41.97, 
57.08, 57.47, 60.61, 62.73, 127.45, 128.36, 128.43, 128.95, 129.23, 
133.62, 137.79, 138.63. (Some aromatic resonances unresolved). 
l2,h Slow band Rf= 0.41 (ethyl acetate). lH NMR 1.75 (m, 8 H), 
2.43 (m, 1 H), 2.65 (m, 1 H), 2.77 (s, 1 H), 3.23 (q, 1 H, J = 5.4 Hz), 
3.37 (q, 1 H, J = 5.7 Hz), 3.65 (t, 2 H, J = 6.1 Hz), 3.67 (d, 1 H, J = 
13.1 Hz), 3.90 (d, 1 H, J = 13.5 Hz), 7.34 (m, 5 H), 7.62 (m, 3 H), 
7.92 (d, 2 H, J = 7.6 Hz). 13C NMR 20.25, 22.33, 23.85, 29.07, 
46.24, 56.71, 57.59, 62.08, 62.32, 127.02, 128.30, 128.66, 128.73, 
129.05, 133.40, 138.60, 138.73. 
7. 8-(phenylsulfonyl)-indolizidine, ll. Piperidine 2.2. (97.9 mg, 
0.26 mmol) was dissolved in 3 mL CH2Cl2. Five drops of triethylamine 
were added to the mixture followed by 20 µL methanesulfonyl chloride 
(MsCl). The reaction appeared complete in 15 min. by TLC ( the 
quatemized salt remains on the baseline, no starting material is observed). 
The solvent was removed in vacuo and the residue was dissolved in 
approximately 2 mL methanol. Palladium hydroxide on carbon (10-20 
mg, 10%; Pearlman's catalyst) was added and the mixture was stirred 
under H2 ( <20 psi) overnight. The mixture was filtered and the solvent 
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was removed in vacuo. The residue was partitioned between 10% NaOH 
and CH2Cb. The combined organic phases were dried and solvent was 
removed in vacuo. The product was purified by elution from florisil 
(ethyl acetate) to give 46.9 mg (67%) of a white solid. IR 2805 cm-1 
(Bohlmann band). 
J.l.a Fast band Rf= 0.07 (ethyl acetate). mp 125-127 °C. HRMS 
rn/z calcd for C14H19NO2S 265.1137, found 265.1120. 1H NMR 
1.49 (m, 1 H), 1.91 (m, 7 H), 2.45 (m, 2 H), 2.62 (dt, 1 H, J = 9.0, 
11.5 Hz), 2.88 (m, 1 H), 3.09 (m, 1 H), 3.60 (quintet, 1 H, J = 4.8 
Hz), 7.61 (m, 3 H), 7.90 (m, 2 H). 13C NMR 20.53, 21.61, 22.51, 
24.02, 48.34, 54.16, 59.19, 62.43, 128.36, 129.03, 133.46, 139.00. 
l1.h Slow band Rf= 0.16 (ethyl acetate). mp 81-82 °C. HRMS 
rn/z calcd for C14H19NO2S 265.1137, found 265.1124. 1H NMR 
1.60 (m, 6 H), 2.08 (m, 5 H), 3.00 (m, 3 H), 7 .62 (m, 3 H), 7 .87 (m, 
2 H). 13C NMR 20.76, 24.62, 25.67, 29.96, 51.64, 53.51, 62.49, 
66.66, 128.76, 129.07, 133.65. 
8. (±)-coniceine, 1. 8-(phenylsulfonyl)-indolizidine Jl (31.6 mg, 0.12 
mmol) was dissolved in 1 mL methanol. An excess of 6% Na/Hg was 
added and the reaction was stirred at room temperature for 2 h. The 
mixture was filtered into 2 mL methanolic HCl to capture the volatile 
indolizidine as the hydrochloride salt. The solvent was removed in vacuo 
followed by partitioning between diethyl ether and 20% KOH to liberate 
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free base. Removal of solvent yielded 10.6 mg indolizidine (71 %). Rf= 
0.06 (ethyl acetate) visualized with ninhydrin stain. IR 2800 cm-1 
(Bohlmann band). 1 H NMR 1.6 (m, 11 H), 2.0 (m, 2 H), 3.0 (m, 2 H). 
13C NMR 20.74 (CH2), 24.66(CH2), 25.65 (CH2), 30.62 (CH2), 31.24 
(CH2), 53.19 (CH2-N), 54.40 (CH2-N), 64.45 (CH). 
9. (2,2-dimethyl-1,3-dioxolan-4-one)-5-ethanoic acid, Ji. S-
malic acid (10 g, 75 mmol) was suspended in 25 mL 2,2-
dimethoxypropane. p-Toluenesulfonic acid monohydrate (p-TsOH; 200 
mg, 1.05 mmol) was added and the mixture was stirred at ambient 
temperature for 30 min. The reaction mixture was partitioned between 
water and CH2Cl2. The aqueous was extracted two additional times and the 
combined organics were dried over N a2SO4. Removal of solvent yielded 
7.47 g of a white solid (57%). Recrystallization from 1:1 CHCl3/CCl4 
yielded 6.16 g (50%) colorless needles. Rf= 0.42 (ethyl acetate). mp 115-
117 °C. [a]0 22 = +6.9° (0.94, CHCb). IR 1720 cm-1 (COOH), 1790 cm-1 
(COOR). lH NMR 1.58 (d, 6 H, J = 15.3 Hz), 2.91 (m, 2 H), 4.70 (m, 1 
H), 9.98 (br s, 1 H). 13C NMR 26.02, 26.96, 36.23, 70.62, 111.61, 
172.11, 175.12. 
10. (2,2-dimethyl-l,3-dioxolan-4-one)-5-ethanol, ll. Acid" 
(5.57 g, 32 mmol) was dissolved in 32 mL THF. The solution was placed 
under Ar and cooled to -78 °C. BH3·THF (35 mL, IM in THF, 35 mmol) 
was added over 40 min. The reaction mixture was allowed to slowly 
equilibrate to ambient temperature and stirred until TLC showed 
consumption of starting material (usually overnight reaction times were 
required). The solvent was removed in vacuo and the borate salts were 
removed by flash chromatography ( 60 g silica, acetone elution) to yield 
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5 .49 g of a light yellow oil (> 100% ). This unstable material was subjected 
to reaction without further purification. Rf= 0.52 (ethyl acetate). [a]o22 = 
+3.7 (0.76, CHC!}). 1 H NMR 1.65 (d, 6 H, J = 15.3 Hz), 2.15 (m, 2 H), 
3.20 (s, 1 H), 3.85 (t, 2 H, J = 6.0 Hz), 4.65 (m, 1 H). 13C NMR 25.64, 
27.08, 34.00, 58.72, 72.09, 110.98, 173.62. 
11. 3-hydroxybutyrolactone, .J§.. Alcohol ~ (5.49 g, 34 mmol) was 
dissolved in 100 mL toluene. p-Toluenesulfonic acid monohydrate (50 mg) 
was added and the mixture was heated to 65 °C for 1 h. After cooling, the 
reaction was quenched with 7 5 mL pyridine. The solvent was removed in 
vacuo to yield 4.23 g of a yellow oil. The product was purified by flash 
chromatography (70 g silica, 40% acetone/petroleum ether elution) to 
provide 2.92 g of a colorless oil (83%). Rf= 0.31 (ethyl acetate). [a]o22 = 
-20.3° (2.2, methanol). IR 1775 cm-1 (C=O). lH NMR 2.28 (m, 1 H), 
2.58 (m, 1 H), 3.70 (bs, 1 H), 4.20 (m, 1 H), 4.42 (dt, 1 H, J = 2.0, 9.0 
Hz), 4.51 (dd, 1 H, J = 8.4, 10.1 Hz). 13C NMR 30.80, 65.19, 67.38 (CH), 
178.10. 
12. 3-(S)-hydroxybutyrolactone, benzyloxy methyl ether, ll- 3-
hydroxybutyrolactone .3.6. (1.68 g, 16.4 mmol) was dissolved in 13 mL 1,2-
dimethoxyethane (DME) under N2, followed by sequential addition of 
diisopropyl ethyl amine (3.37 mL, 19.3 mmol) and benzyl chloromethyl 
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ether (3.6 mL, 25.9 mmol). The reaction mixture was heated at 65 °C.for 
2 h. The cooled mixture was diluted with water followed by three 
extractions with CH2Cl2. The combined organic layers were dried over 
Na2SO4. Removal of solvent provided a yellow oil which was 
chromatographed (60 g silica, 30% ethyl acetate/petroleum ether elution) 
to yield 2.87 g of a clear, colorless oil (79%). Rf= 0.42 (diethyl ether). 
[a]o22 = -81.67° (1.86, CHCl3). lH NMR 2.25 (m, 1 H), 2.51 (m, 1 H), 
4.20 (td, 1 H, J = 6.5, 9.3 Hz), 4.40 (dt, 1 H, J = 3.0, 8.8 Hz), 4.47 (dd, 1 
H, J = 8.1, 9.1 Hz), 4.68 (d, 2 H, J = 2.3 Hz), 4.87 (d, 1 H, J = 7.1 Hz), 
5.07 (d, 1 H, J = 7.1 Hz), 7.32 (m, 5 H). 13C NMR 29.86 (CH2), 65.11 
(CH2), 70.15 (CH2), 70.39 (CH), 94.02 (O-CH2-O), 127.89, 127.99, 
128.40, 128.51, 174.85. 
13. 3-(S)-hydroxybutyrolactol, 3-benzyloxy methyl ether, J.8,. 
Lactone IZ (2.20 g, 9 .9 mmol) was dissolved in 100 mL diethyl ether. 
The reaction mixture was cooled to -78 °C. 10.0 mL 1.0 M DIBAL-H was 
added and the mixture was allowed to slowly equilibrate to O °C. After 4 
h, 100 mL 1 % Na OH was added and the mixture was extracted thrice with 
diethyl ether. Removal of solvent followed by column purification (1: 1 
CH2Cb/petroleum ether) yielded 1.61 g of a clear, colorless oil (73% ). Rf 
= 0.34 (diethyl ether). [a] 0 22 = +33.7° (2.3, CHCb). IR 3420 cm-1(OH), 
1785 cm-1 (C=O). Anal. calcd for C12H16O4: C, 64.27; H, 7.19. Found: 
C, 64.71; H, 7.35. lH NMR 2.10 (m, 2 H), 3.04 (s, 1 H), 4.07 (m, 2 H), 
4.21 (m, 1 H), 4.63 (m, 2 H), 4.83 (m, 2 H), 5.36 (m, 1 H), 7.30 (m, 5 H). 
13C NMR 29.81, 29.86, 64.77, 66.88, 69.69, 70.08, 76.65, 81.33, 93.67, 
94.32, 96.36, 101.05, 127.74, 127.83, 127.92, 128.43, 128.51, 137.57 .. 
(Mixture of a- and ~- anomers ). 
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14. N-benzylidene, 2-(S)-benzyloxymethylether-4-hydroxy-
butanal, fi. A solution containing 0.625 g lactol J.B. (2.8 mmol) in 1 mL 
toluene was added to a stirred solution of 0.38 g benzylamine (1.25 eq) in 2 
mL toluene. The mixture was stirred at ambient temperature for greater 
than 10 h followed by removal of the solvent in vacuo. The residue was 
heated to 60-80 °Cat 0.5 mm to remove unreacted benzylamine, yielding 
0.869 g of a yellow oil (99.5% ). This product was not stable and was 
submitted to further reaction without purification. Rf= 0.5 (diethyl ether). 
IR 1660 cm-1 (C=N). lH NMR (60 MHz) 1.6-2.3 (m, 2 H), 2.45 (s, 2 H), 
3.5-4.2 (m, 4 H), 4.65 (s, 2 H), 4.85 (s, 2 H), 7 .35 ( d, 10 H). 
15. 1-benzyl-5-(phenylsulfonyl)-6-[l-benzyloxymethoxy-3-
hydroxypropyl]-2-piperidone, ,il. Imine il (0.869 g, 2.8 mmol) was 
dissolved in 5 mL THF. The mixture was cooled to -78 °C and 1.0 mL 
boron trifluoride etherate (3.0 eq) was added. After 0.5 h, this mixture 
was added to a dianion solution prepared as follows: 4-PSBA (1.28 g, 5.6 
mmol) was dissolved in 75 ml THF and cooled to -78 °C. Butyllithium 
( 4.5 mL, 2.5 M, 11.2 mmol) was added dropwise to give a clear, yellow 
solution. Upon addition of the complexed imine to this dianion solution, 
the color was discharged. The mixture was allowed to slowly equilibrate 
to 0 °C whereupon 1.5 mL TFAA was added. After 0.5 h, the reaction was 
partitioned between ethyl acetate and saturated Na2CO3. A total of three 
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ethyl acetate extractions were performed and the combined organic phases 
were dried over Na2SO4. Removal of solvent yielded 1.543 g of a yellow 
oil (>100%). Column purification (ethyl acetate elution) provided two 
products of Rf= 0.21, 0.11 designated as fast and slow bands, respectively, 
in a total yield of 0.395 g (27%). Anal calcd. for C29H33NO6S·½ H2O: C, 
65.39; H, 6.43; N, 2.63. Found: C, 65.68; H, 6.29; N, 2.68. 
ila Fast band [a] 0 22 = -5.3° (0.34, CHCI}). IR 3500 cm-1 (OH), 
1640 cm-1 (C=O, strong). lH NMR 1.54 (m, 2 H), 2.13 (m, 2 H), 
2.53 (m, 2 H), 3.53 (m, 3 H), 4.04 (d, 1 H, J = 14.8 Hz), 4.06 (m, 2 
H), 4.52 (d, 2 H, J = 3.9 Hz), 4.56 (d, 1 H, J = 6.8 Hz), 4.73 (d, 1 H, 
J = 6.8 Hz), 5.30 (d, 1 H, J = 14.7 Hz), 7.29 (m, 10 H), 7.44 (m, 2 
H), 7.58 (m, 3 H). 13C NMR 21.06, 29.46, 33.78, 48.27, 56.48 
(CH), 58.48 (CH), 58.77, 70.36, 76.47 (CH), 94.66, 127.52, 127.63, 
127.69, 127.86, 128.42, 128.51, 128.56, 128.75, 128.89, 129.07, 
129.19, 129.23, 133.92, 136.31, 136.67, 136.69, 136.95, 170.98. 
(Some aromatic resonances unresolved). 
ill Slow band [a]o22 = - 63.46° (0.26, CHCl3). White crystals 
from CHCb/ diethyl ether, mp= 153.5-154.5 °C. IR 3500 cm-1 
(OH), 1640 cm-1 (C=O, strong) lH NMR 1.52 (m, 1 H), 1.75 (m, 1 
H), 2.18 (m, 2 H), 2.57 (m, 2 H), 2.93 (m, 1 H), 3.66 (m, 3 H), 3.94 
(m, 3 H), 3.99 (d, 1 H, J = 14.9 Hz), 4.19 (m, 1 H), 4.40 (d, 1 H, J = 
12.0 Hz), 4.58 (d, 1 H, J = 12.1 Hz), 5.61 (d, 1 H, J = 14.9 Hz), 7.44 
(m, 15 H). 13C NMR 18.86, 28.47, 32.51, 48.08, 53.93(CH), 
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56.52(CH), 58.75, 70.08, 72.83(CH), 93.17, 127.61, 127.81, 128.01, 
128.53, 128.69, 128.83, 129.16, 129.29, 133.79, 136.19, 136.95, 
137.05, 169.97. (Some aromatic resonances unresolved). 
16. 2-(1-benzyloxymethoxy-3-hydroxypropyl)-3-
(phenylsulfonyl)-N-benzyl-piperidine, il. Piperidone il (0.105 g, 
0.2 mmol) was dissolved in 5 mL THF. The mixture was cooled to 0° C 
and 0.6 mL of IM BH3·THF (3.0 eq) was added dropwise. The mixture 
was allowed to slowly warm to room temperature and stirred overnight. 
The reaction was quenched by addition of 5 drops 5% NaOH and 
partitioned between CH2Cli and saturated Na2CO3. A total of three 
extractions were performed. The combined organic phases were dried 
over Na2SO4. Removal of solvent in vacuo yielded 95.1 mg of a pale 
yellow oil. The product was purified on florisil (ethyl acetate with 1 % 
TEA elution) to yield 84.5 mg of a clear, colorless oil (84% ). 
lli Fast band Rf= 0.34 (diethyl ether). [a]o22 = +13.0° (0.52, 
CHCb). HRMS m/z calcd for C29H35NO5S 509.2236, found 
509.2316. lH NMR 1.25 (m, 1 H), 1.98 (m, 5 H), 2.70 (m, 2 H), 
2.82 (bs, 1 H), 3.65 (m, 4 H), 4.11 (s, 2 H), 4.17 (m, 1 H), 4.52 (d, 1 
H, J =11.9 Hz), 4.56 (d, 1 H, J = 11.9 Hz), 4.82 (d, 1 H, J = 14.7 
Hz), 4.84 (d, 1 H, J = 14.7 Hz), 7.19 (m, 2 H), 7.36 (m, 8 H), 7.62 
(m, 3 H), 7.99 (d, 2 H, J = 7.1 Hz). 13C NMR 16.62, 20.95, 35.34, 
45.07, 46.25, 57.74(CH), 58.18(CH), 59.24, 70.39, 75.96, 94.52, 
126.98, 127.44, 127.80, 128.19, 128.29, 128.42, 128.54, 128.69, 
129.04, 129.08, 133.37, 137.14, 139.08, 139.25. (Some aromatic 
resonances unresolved). 
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~ Slow band Rf= 0.29 (diethyl ether). [a]o22 = -46.5° (0.16, 
CHCb). lH NMR 1.50 (m, 1 H), 2.01 (m, 5 H), 2.74 (m, 1 H), 2.92 
(m, 1 H), 3.50 (m, 2 H), 3.58 (t, 1 H, J = 4.2 Hz), 3.70 (m, 2 H), 
3.98 (d, 1 H, J = 13.7 Hz), 4.09 (d, 1 H, J = 13.7 Hz), 4.18 (q, 1 H, J 
= 6.0 Hz), 4.53 ( d, 1 H, J = 11.9 Hz), 4.58 (s, 2 H), 4.64 ( d, 1 H, J = 
11.9 Hz), 7.37 (m, 10 H), 7.53 (m, 2 H), 7.63 (m, 1 H), 7.89 (m, 2 
H). 13C NMR 17.64, 21.77, 35.03, 45.95, 57.25(CH), 58.51(CH), 
58.56, 58.97, 70.27, 78.59(CH), 94.78, 127.11, 127.57, 127.77, 
128.29, 128.43, 128.69, 129.01, 129.04, 133.37, 137.40, 138.35, 
138.93. (Some aromatic resonances unresolved). 
17. 8-(phenylsulfonyl)-1-benzyloxymethoxy-indolizidine, .iS,. A 
general procedure is presented: The piperidine was dissolved in 
CH2Cli(approximately 25 mg/mL). Excess K2CO3, 5 drops TEA, and 1 
eq. methanesulfonyl chloride were added sequentially. After 2 h, the 
mixture was filtered and the solvent was removed. The residue was 
dissolved in methanol (1-2 mL) and subjected to hydrogenolysis (100 mg 
Pearlman's catalyst, 39 psi H2) for > 4 h. The solution was filtered and the 
solvent was removed in vacuo. Column purification (florisil, ethyl acetate 
with 1 % TEA elution) provided the products as lightly yellow oils. 
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~ Fast band 85 .4 mg piperidine reacted, 146.1 mg crude 
mesylate obtained, 69.1 mg crude indolizidine obtained (98%), 27.5 
mg pure indolizidine recovered (40%). Rf= 0.31 (ethyl acetate). 
[a]o23 = -65.8° (0.16, CHCb). HRMS m/z calcd for C22H27NO4S 
401.1661, found 401.1608. lH NMR 1.32 (dq, 1 H, J = 4.5, 12.7 
Hz), 1.64 (m, 2 H), 1.95 (m, 2 H), 2.16 (m, 2 H), 2.33 (dd, 1 H, J = 
5.4, 9.9 Hz), 2.47 (m, 1 H), 3.03 (m, 3 H), 4.57 (dt, 1 H, J = 2.0, 6.0 
Hz), 4.69 (d, 1 H, J = 11.8 Hz), 4.87 (d, 1 H, J = 11.9 Hz), 5.02 (d, 1 
H, J = 7.0 Hz), 5.08 (d, 1 H, J = 7.0 Hz), 7.38 (m, 5 H), 7.65 (m, 3 
H), 8.00 (m, 2 H). 13C NMR 24.15, 27.10, 31.60, 51.46, 52.10, 
64.72, 68.81, 70.11, 81.56, 96.30, 127.54, 127.74, 128.36, 128.93, 
129.23, 129.34, 133.55, 137.57, 138.10. (Some aromatic resonances 
unresolved) . 
.iS,h Slow band 171.1 mg piperidine reacted, 234.2 mg crude 
mesylate obtained, 141 mg crude indolizidine obtained (100%), 72.8 
mg pure indolizidine recovered (52% ). Rf= 0.29 (ethyl acetate). 
[a]o23 = -5.1 ° (0.22, CHCb). HRMS m/z calcd for C22H27NO4S 
401.1661, found 401.1663. lH NMR 1.30 (t, 1 H, J = 7.3 Hz), 1.77 
(m, 5 H), 2.19 (m, 2 H), 3.11 (m, 3 H), 3.61 (m, 1 H), 4.67 (m, 1 
H), 4.72 (d, 1 H, J = 11.8 Hz), 4.86 (d, 1 H, J = 11.8 Hz), 4.93 (d, 1 
H, J = 7.1 Hz), 5.09 (d, 1 H, J = 7.1 Hz), 7.37 (m, 5 H), 7.62 (m, 3 
H), 7.95 (m, 2 H). 13C NMR 23.92, 25.29, 30.40, 51.64, 51.96, 
60.06, 64.94, 70.02, 78.42, 95.81, 127.47, 127.63, 127.68, 128.15, 
128.31, 128.67, 128.90, 129.05, 129.28, 133.60, 137.90, 138.18. 
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18. l(S)-hydroxy-8-(phenylsulfonyl)-indolizidine, !6,. 
Indolizidine ,i5 (65.8 mg, 0.16 mmol) was dissolved in approximately 3 
mL methanol. 20 mg of 10% Pd/C and 10 µL TF A were added. The 
mixture was stirred under 10-20 psi H2 at ambient temperature for greater 
than 10 h. The solution was filtered and the solvent was removed in vacuo 
to yield 49 .3 mg of a brown oil. The product was purified on florisil 
(ethyl acetate) to give 27.3 mg (54%) of a clear, colorless oil. 
.i6.,a Fast band Rf= 0.21 (ethyl acetate). [a] 0 23 = -13.7° (0.8, 
methanol). HRMS m/z calcd for C14H19NO3S 281.1086, found 
281.1108. lH NMR 1.28 (dq, 1 H, J = 4.4, 12.8 Hz), 1.45 (m, 1 H), 
1.69 (m, 2 H), 1.83 (m, 1 H), 1.97 (dt, 1 H, J = 2.9, 11.6 Hz), 2.11 
(dd, 1 H, J = 6.6, 10.0 Hz), 2.31 (m, 1 H), 2.42 (q, 1 H, J = 8.9 Hz), 
2.95 (m, 3 H), 4.09 (d, 1 H, J = 2.8 Hz), 4.39 (m, 1 H), 7.62 (m, 3 
H), 7.90 (m, 2 H). 13C NMR 24.29, 26.29, 30.29, 51.58, 52.15, 
66.31, 69.22, 74.96, 129.12, 129.22, 134.05. (Some aromatic 
resonances unresolved) . 
.i6.b. Slow band Rf= 0.14 (ethyl acetate). [a] 0 23 = +35.2° (1.1, 
methanol). HRMS m/z calcd for C14H19NO3S 281.1086, found 
281.1097. lH NMR 1.82 (m, 10 H), 3.16 (dt, 1 H, J = 1.7, 8.9 Hz), 
3.19 (m, 3 H), 7.60 (m, 3 H), 7.85 (m, 2 H). 13C NMR 24.10, 
25.57, 30.99, 51.87, 52.94, 61.23, 67.33, 71.29, 128.44, 128.83, 
129.11, 129.22, 129.26, 134.05. 
63 
19. ( + )-(1S, 8aS)-1-hydroxyindolizidine, .8,. Indolizidine il (16.4 
mg, 0.058 mmol) was dissolved in 2 mL methanol and excess Na/Hg was 
added. The mixture was stirred at room temperature for 2 h. The solution 
was filtered into a flask containing 1-2 mL acidic methanol(methanol 
saturated with HCl(g)). The solvent was removed in vacuo to provide a 
yellow solid. The residue was dissolved in 2 mL water and 3 pellets KOH 
were added, followed by three extractions with diethyl ether. The 
combined organics were dried over Na2SO4 and the solvent was removed 
in vacuo to yield 6.8 mg lightly yellow oil (83%). Filtration through 
florisil to remove the color provided 5.5 mg clear oil (67%). From fast 
[a]n22 = +16.4° (0.28, CDCl3). HRMS m/z calcd for CgH15NO 141.1154, 
found 141.1157. From slow [o;Jo22= +18.1 ° (0.42, CDCl3). HRMS m/z 
calcd for CgH15NO 141.1154, found 141.1150. IR 2800 cm-1 (Bohlmann 
band). lH NMR 1.77 (m, 10 H), 3.00 (m, 2 H), 3.47 (s, 1 H), 4.00 (m, 1 
H). 13C NMR 24.08, 25.04, 28.79, 31.83, 52.54, 53.29, 71.11, 76.41. 
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Chapter 8 
Selected 2-D HOMCOR assignments. 
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